Pharmosa Biopharm Inc. (TPEX:6875)
Taiwan · Delayed Price · Currency is TWD 51.90
+0.10 (0.19%)
Dec 31, 2025, 1:30 PM CST
Pharmosa Biopharm Revenue
Pharmosa Biopharm had revenue of 4.00M TWD in the quarter ending September 30, 2025, a decrease of -90.23%. This brings the company's revenue in the last twelve months to 136.72M, up 170.62% year-over-year. In the year 2024, Pharmosa Biopharm had annual revenue of 167.57M, down -46.72%.
Revenue (ttm)
136.72M
Revenue Growth
+170.62%
P/S Ratio
49.00
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 167.57M | -146.93M | -46.72% |
| Dec 31, 2023 | 314.50M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.10B |
| Lotus Pharmaceutical | 18.66B |
| PharmaEssentia | 13.82B |
| Pegavision | 6.90B |
| Center Laboratories | 1.57B |
| Oneness Biotech | 117.33M |
| Polaris Group | 70.83M |
| Lumosa Therapeutics | 42.59M |